Cubist Pharmaceuticals has selected Robert J. Perez as the company's CEO, effective January, 2015. Perez, who currently is Cubist's president and chief operating officer, will succeed Michael W. Bonney who is retiring from his current role as CEO on Dec. 31, and will become non-executive chair of Cubist's board of directors. Current board chair Kenneth M. Bate will become lead independent director.
Perez has worked in various senior positions at Cubist for 11 years. He was appointed chief operating officer in 2007, president in 2012 and has been a member of the board since April.
Previously, Perez was vice president of Biogen's CNS business unit where he was responsible for leading the U.S. neurology franchise. From 1995 to 2001, he was a regional director, director of sales, and Avonex commercial executive at Biogen. From 1987 to 1995, Perez held various sales and marketing positions at Zeneca Pharmaceuticals. Perez is a director at AMAG Pharmaceuticals and from 2006-2009 was a director at EPIX Pharmaceuticals.
He also is a trustee of the Dana-Farber Cancer Institute and a director of the California Healthcare Institute, the Biomedical Science Careers Program and a member of the board of advisors of Citizen Schools of Massachusetts.